Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.

Authors

Charles Drake

Charles G. Drake

Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY

Charles G. Drake, Daniel Peter Petrylak, Emmanuel S. Antonarakis, Adam S. Kibel, Nancy N. Chang, Tuyen Vu, Dwayne Campogan, Heather Haynes, James B. Trager, Nadeem Anwar Sheikh, David I. Quinn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells

Sub Track

Vaccines: Treatment and Prevention

Clinical Trial Registration Number

NCT01431391; NCT01981122

Citation

J Clin Oncol 35, 2017 (suppl 7S; abstract 163)

DOI

10.1200/JCO.2017.35.7_suppl.163

Abstract #

163

Poster Bd #

J2

Abstract Disclosures

Similar Posters

Poster

2016 Genitourinary Cancers Symposium

Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.

Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.

First Author: Emmanuel S. Antonarakis

First Author: Tomasz M. Beer